- Home
- SLP vs VCRE Comparison
SLP vs VCRE Comparison
Compare SLP & VCRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SLP | VCRE |
|---|---|---|
| Founded | 1996 | N/A |
| Country | United States | Sweden |
| Employees | N/A | 40 |
| Industry | EDP Services | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 370.7M | 332.9M |
| IPO Year | 1996 | N/A |
Fundamental Metrics
Financial Performance| Metric | SLP | VCRE |
|---|---|---|
| Price | $18.35 | $12.59 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $24.00 | N/A |
| AVG Volume (30 Days) | ★ 368.0K | 2.3K |
| Earning Date | 04-09-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.43 | N/A |
| Revenue | ★ $59,577,000.00 | N/A |
| Revenue This Year | $3.80 | N/A |
| Revenue Next Year | $5.90 | N/A |
| P/E Ratio | $42.58 | ★ N/A |
| Revenue Growth | ★ 10.52 | N/A |
| 52 Week Low | $11.09 | $10.50 |
| 52 Week High | $21.01 | $12.85 |
Technical Indicators
Market Signals| Indicator | SLP | VCRE |
|---|---|---|
| Relative Strength Index (RSI) | 60.61 | 33.17 |
| Support Level | $18.20 | $10.50 |
| Resistance Level | $18.39 | $11.59 |
| Average True Range (ATR) | 0.05 | 0.36 |
| MACD | -0.04 | 0.04 |
| Stochastic Oscillator | 67.65 | 9.38 |
Price Performance
Historical ComparisonAbout SLP Simulations Plus Inc.
Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.
About VCRE Vicore Pharma Holding AB American Depositary Shares
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.